Get the Stockscreener App
14.85
1.57%
0.23
Edgewise Therapeutics Inc stock is traded at $14.85, with a volume of 570.32K.
It is up +1.57% in the last 24 hours and up +9.68% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$14.62
Open:
$14.73
24h Volume:
570.32K
Relative Volume:
0.74
Market Cap:
$1.56B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-9.5806
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
+4.95%
1M Performance:
+9.68%
6M Performance:
-45.14%
1Y Performance:
-24.20%
1-Day Range:
$14.62
$15.21
1-Week Range:
$13.53
$15.21
52-Week Range:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.85 | 1.47B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Deutsche Bank AG Raises Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Volume Surge May Signal Institutional Interest in Edgewise Therapeutics Inc.July 2025 Catalysts & Verified Chart Pattern Signals - classian.co.kr
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 2,862 Shares of Stock - MarketBeat
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 1,907 Shares of Stock - MarketBeat
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) CEO Sells 7,972 Shares of Stock - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel John R. Moore Sells 2,098 Shares - MarketBeat
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) CFO Sells 1,428 Shares of Stock - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - GlobeNewswire Inc.
What makes Edgewise Therapeutics Inc. stock price move sharplyTechnical Signal Trend Tracker Strategy - beatles.ru
Traders Consider Averaging Down in Edgewise Therapeutics Inc.Gold Moves & Technical Entry and Exit Alerts - sisa-n.com
Is Edgewise Therapeutics Inc. stock entering bullish territoryWeekly Profit Recap & Free Safe Entry Trade Signal Reports - Newser
What candlestick patterns are forming on Edgewise Therapeutics Inc.2025 Technical Overview & Reliable Volume Spike Alerts - Newser
Heatmap analysis for Edgewise Therapeutics Inc. and competitorsJuly 2025 Technicals & AI Driven Price Forecasts - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - cnhinews.com
Key resistance and support levels for Edgewise Therapeutics Inc.2025 Key Highlights & Technical Pattern Alert System - Newser
Real time scanner hits for Edgewise Therapeutics Inc. explainedJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
Quantitative breakdown of Edgewise Therapeutics Inc. recent move2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Is Edgewise Therapeutics Inc. stock poised for growth2025 Short Interest & Accurate Technical Buy Alerts - Newser
How sentiment analysis helps forecast Edgewise Therapeutics Inc.Trade Exit Summary & Risk Controlled Stock Alerts - Newser
Intraday pattern recognizer results for Edgewise Therapeutics Inc.2025 Earnings Impact & Technical Entry and Exit Tips - Newser
Using AI based signals to follow Edgewise Therapeutics Inc.Weekly Gains Report & Stepwise Entry/Exit Trade Alerts - Newser
Applying Wyckoff theory to Edgewise Therapeutics Inc. stock2025 Winners & Losers & Verified Technical Signals - Newser
Wedbush Research Analysts Lower Earnings Estimates for EWTX - MarketBeat
Will Edgewise Therapeutics’ (EWTX) Rising Losses Reshape Its Long-Term Investment Strategy? - simplywall.st
Edgewise Therapeutics CBO sells shares worth $33,360 By Investing.com - Investing.com South Africa
Edgewise Therapeutics general counsel sells $28k in shares By Investing.com - Investing.com Canada
Edgewise Therapeutics CMO sells $38,329 in shares By Investing.com - Investing.com Canada
Edgewise Therapeutics CEO Kevin Koch sells $106k in shares By Investing.com - Investing.com South Africa
Edgewise Therapeutics CMO sells $38,329 in shares - Investing.com
Edgewise Therapeutics CFO sells $19k in shares By Investing.com - Investing.com Canada
Edgewise Therapeutics CSO sells $25,539 in EWTX stock By Investing.com - Investing.com India
Edgewise Therapeutics CBO sells shares worth $33,360 - Investing.com India
Edgewise Therapeutics CEO Kevin Koch sells $106k in shares - Investing.com India
Edgewise Therapeutics CFO sells $19k in shares - Investing.com India
Edgewise Therapeutics CSO sells $25,539 in EWTX stock - Investing.com
Edgewise Therapeutics general counsel sells $28k in shares - Investing.com
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOORE JOHN R | General Counsel |
Aug 12 '25 |
Sale |
13.39 |
2,098 |
28,097 |
10,214 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '25 |
Option Exercise |
0.00 |
5,781 |
0 |
26,136 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '25 |
Sale |
13.39 |
2,491 |
33,360 |
23,645 |
| Carruthers R Michael | Chief Financial Officer |
Aug 12 '25 |
Option Exercise |
0.00 |
5,781 |
0 |
87,590 |
| Carruthers R Michael | Chief Financial Officer |
Aug 12 '25 |
Sale |
13.39 |
1,428 |
19,124 |
86,162 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '25 |
Option Exercise |
0.00 |
5,781 |
0 |
25,307 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '25 |
Sale |
13.39 |
1,907 |
25,539 |
23,400 |
| KOCH KEVIN | President and CEO |
Aug 12 '25 |
Option Exercise |
0.00 |
17,968 |
0 |
38,587 |
| KOCH KEVIN | President and CEO |
Aug 12 '25 |
Sale |
13.39 |
7,972 |
106,764 |
30,615 |
| Donovan Joanne M. | CMO |
Aug 12 '25 |
Option Exercise |
0.00 |
5,781 |
0 |
28,223 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):